ODTX ▼ -0.3% - Odyssey Therapeutics, Inc.
$ODTX - Odyssey Therapeutics to Present Design of Phase 2a Study Evaluating OD-001 in Combination with Vedolizumab at ACG 2026
12-OCT-2026 08:00 AM ET
Share this post
More filings for $ODTX
ODTX ▼ -0.6% - Odyssey Therapeutics, Inc.Oct 6, 2026ODTX ▼ -2.7% - Odyssey Therapeutics, Inc.Sep 16, 2026
View full $ODTX filing history →💬 Comments
Loading comments…
Leave a comment